

COMPLETE GENOMICS INC  
Form 4  
November 16, 2010

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
ENTERPRISE PARTNERS V L P

2. Issuer Name and Ticker or Trading Symbol  
COMPLETE GENOMICS INC  
[GNOM]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
11/16/2010

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_ Other (specify below)

C/O ENTERPRISE PARTNERS, 2223 AVENIDA DE LA PLAYA, SUITE 300

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

LA JOLLA, CA 92037-3218

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value \$0.001	11/16/2010		C		176,737	A	(1) 176,737
Common Stock, par value \$0.001	11/16/2010		C		259,458	A	(5) 436,195
Common Stock, par	11/16/2010		X		138,794	A	\$ 574,989 7.56

Edgar Filing: COMPLETE GENOMICS INC - Form 4

value \$0.001								
Common Stock, par value \$0.001	11/16/2010	F	23,133	D	\$ 9	551,856	D <sup>(2)</sup>	
Common Stock, par value \$0.001	11/16/2010	X	17,261	A	\$ 7.56	569,117	D <sup>(2)</sup>	
Common Stock, par value \$0.001	11/16/2010	F	14,500	D	\$ 9	554,617	D <sup>(2)</sup>	
Common Stock, par value \$0.001	11/16/2010	X	8,378	A	\$ 7.56	562,995	D <sup>(2)</sup>	
Common Stock, par value \$0.001	11/16/2010	F	7,038	D	\$ 9	555,957	D <sup>(2)</sup>	
Common Stock, par value \$0.001	11/16/2010	P <sup>(6)</sup>	111,111	A	\$ 9	667,068	D <sup>(2)</sup>	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount of Number of Shares
Series D Preferred	<u>(1)</u>	11/16/2010		C	176,737	<u>(3)</u>	<u>(4)</u>	Common Stock	176,737

Stock <sup>(1)</sup>

Series E Preferred Stock <sup>(1)</sup>

	(1)	11/16/2010	C	259,458	(3)	(4)	Common Stock	259,458
--	-----	------------	---	---------	-----	-----	--------------	---------

Warrant to Purchase Common Stock

	\$ 1.5	11/16/2010	X	138,794	(5)	08/12/2016	Common Stock	138,794
--	--------	------------	---	---------	-----	------------	--------------	---------

Warrant to Purchase Series D Preferred Stock

	\$ 7.56	11/16/2010	X	17,261	(5)	04/06/2014	Common Stock	17,261
--	---------	------------	---	--------	-----	------------	--------------	--------

Warrant to Purchase Series D Preferred Stock

	\$ 7.56	11/16/2010	X	8,378	(5)	06/12/2014	Common Stock	8,378
--	---------	------------	---	-------	-----	------------	--------------	-------

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director    10% Owner    Officer    Other

ENTERPRISE PARTNERS V L P  
C/O ENTERPRISE PARTNERS  
2223 AVENIDA DE LA PLAYA, SUITE 300  
LA JOLLA, CA 92037-3218

X

## Signatures

/s/ Andrew E. Senyei, Managing Director, Enterprise Partners V, L.P.

11/16/2010

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Each share of Series D and Series E Preferred Stock was automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering.

The shares are owned by Enterprise Partners V, LP ("Enterprise V"). Enterprise Management Partners V, LLC ("Enterprise V LLC") serves as the general partner of Enterprise V. Andrew E. Senyei, M.D. is a managing director of Enterprise V LLC and shares voting and investment power over the shares held by Enterprise V.

(3) The securities are immediately convertible.

(4) The expiration date is not relevant to the conversion of these securities.

## Edgar Filing: COMPLETE GENOMICS INC - Form 4

- (5) The warrant is immediately exercisable.
- (6) Enterprise V purchased an additional 111,111 shares of Issuer's common stock in connection with the initial public offering at the offering price of \$9.00 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.